Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Nanobiotix is a biotechnology business based in the US. Nanobiotix shares (NBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Nanobiotix employs 102 staff and has a trailing 12-month revenue of around $4.8 million.
tastytrade
Finder Award
SoFi Invest
M1 Finance
| Latest market close | $5.03 |
|---|---|
| 52-week range | $1.75 - $7.76 |
| 50-day moving average | $4.00 |
| 200-day moving average | $3.94 |
| Wall St. target price | $8.70 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.68 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.03 from 2023-06-02
| 1 week (2023-05-26) | 4.34% |
|---|---|
| 1 month (2023-05-05) | -24.70% |
| 3 months (2023-03-03) | 42.57% |
| 6 months (2022-12-05) | 31.50% |
| 1 year (2022-06-03) | -0.61% |
|---|---|
| 2 years (2021-06-04) | -71.73% |
| 3 years (2020-06-01) | N/A |
| 5 years (2018-06-01) | N/A |
| Revenue TTM | $4.8 million |
|---|---|
| Gross profit TTM | $4.8 million |
| Return on assets TTM | -35.38% |
| Return on equity TTM | -198.69% |
| Profit margin | 0% |
| Book value | $-0.78 |
| Market capitalisation | $184.2 million |
TTM: trailing 12 months
We're not expecting Nanobiotix to pay a dividend over the next 12 months.
Over the last 12 months, Nanobiotix's shares have ranged in value from as little as $1.75 up to $7.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nanobiotix's is 1.7195. This would suggest that Nanobiotix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Nanobiotix's beta into context you can compare it against those of similar companies.
Nanobiotix S. A. , a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S. A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.